Erlichman et al., J Clin Oncol 2006
(Neoplasms) :
The maximum tolerated dose ( MTD ) and the dose limiting toxicities of EKB-569 , a selective, irreversible inhibitor of the epidermal growth factor receptor (EGFR) , when administered orally once daily on an intermittent-dose schedule ( 14 days of a 28-day cycle ) or on a continuous-dose schedule ( each day of a 28-day cycle ), were determined in patients with advanced solid tumors
Folprecht et al., Clin Cancer Res 2008
(Colorectal Neoplasms) :
To determine the recommended dose ( RD ) of EKB-569 , an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor , in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer ( mCRC )